Alimentary Pharmacology & Therapeutics

VOLUME 15 PAGES 1–2066 2001

Editors
R E Pounder and W L Peterson

Editorial Board

Chairman J-R Malagelada
R Arnold
A T R Axon
K D Bardhan
G Bianchi Porro
M Camilleri
M Classen
H G Dammann
G Delle Fave
W Domschke
M Feldman
B M Fennerty
R L Fisher
A G Fraser
D N Granger
N J Greenberger
E G Hahn
S B Hanauer
C J Hawkey
R V Heatley
H J F Hodgson
R Hunt
K Kawai
K Kimura
G J Krejs
L A Laine
S K Lam
R Lambert
C B H W Lamers
M J S Langman
A Lee
K E L McColl
P Malfertheiner
M Mignon
S Okabe
C O'Morain
D S Rampton
J Rask-Madsen
J M Rhodes
J Rhodes
P Rutgeerts
R A Smallwood
J J Y Sung
C Takemoto
N J Talley
A Terano
W J Tremaine
L A Turnberg
G N Tytgat
J L Wallace
R P Walt
M Wolfe
S-D Xiao

b
Blackwell Science

© 2001 Blackwell Science
Published by Blackwell Science Ltd
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ

Other Editorial Offices:
Blackwell Science Inc., Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA
Blackwell Science (France) Ltd, 10 rue Casimir Delavigne, 75006 Paris, France
Blackwell Science Asia, 54 University Street, Carlton, Victoria 3053, Australia
Blackwell Wissenschafts-Verlag GmbH, Kurfürstendamm 57, D-10707 Berlin, Germany
Blackwell Science KK, MG Kodemmacho Building, 7–10 Kodemmacho, Nihombashi, Chuo-ku, Tokyo 104, Japan

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01973, USA. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to the Editor, *Alimentary Pharmacology & Therapeutics*. ISSN 0269–2813/01 $15.00

Alimentary Pharmacology & Therapeutics is included in the major information retrieval systems, including Index Medicus and Medine, the CINAHL index, CABS Science Citation Index, Current Contents—Life Sciences, Excerpta Medica and Current Opinion in Gastroenterology

ISSN 0269–2813
Typset by SPS, Chennai, India, and printed at Bell & Bain, Glasgow, UK

Contents

VOLUME 15 NUMBER 1 JANUARY

1 Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. C. J. HAWKEY, L. JACKSON, S. E. HARPER, T. J. SIMON, E. MORTENSEN & C. R. LINES

11 Effect of *Lactobacillus* ingestion on the gastrointestinal mucosal barrier alterations induced by indomethacin in humans. M. GOTTELAND, S. CRUCHET & S. VERBEKE

19 Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. F. K. L. CHAN, J. J. Y. SUNG, J. Y. L. CHING, J. C. Y. WU, Y. T. LEE, W. K. LEUNG, Y. HUI, L. Y. CHAN, A. C. W. LAI & S. C. S. CHUNG

25 Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. K. F. TO, F. K. L. CHAN, A. S. L. CHENG, T. L. LEE, Y. P. NG & J. J. Y. SUNG

35 Efficacy of parenteral methotrexate in refractory Crohn's disease. R. Y. CHONG, S. B. HANAUER & R. D. COHEN

45 Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. P. LUNDIN, T. NABER, M. NILSSON & S. EDSBÄCKER

53 Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. F. N. HUSSAIN, R. A. AJJAN, K. KAPUR, M. MOUSTAFA & S. A. RILEY

63 *Helicobacter pylori* screening for individuals requiring chronic NSAID therapy: a decision analysis. J. M. SCHEIMAN, R. R. BANDEKAR, M. E. CHERNEW & A. M. FENDRICK

73 Accuracy of the stool antigen test in the diagnosis of *Helicobacter pylori* infection before treatment and in patients on omeprazole therapy. G. MANES, A. BALZANO, G. IAQUINTO, C. RICCI, M. M. PICCIRILLO, N. GIARDULLO, A. TODISCO, M. LIONIELLO & D. VAIRA

81 A multicentre study on eradication of *Helicobacter pylori* using four 1-week triple therapies in China. CHINESE NATIONAL COOPERATIVE STUDY GROUP FOR *HELICOBACTER PYLORI*: S.-D. XIAO, W.-Z. LIU, P.-J. HU, Q. OUYANG, J.-L. WANG, L.-Y. ZHOU & N.-N. CHENG

87 *Helicobacter pylori* effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. B. I. HIRSCHOWITZ & M. M. HABER

105 Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. N. BELL, M. D. KAROL, G. SACHS, P. GRESKI-ROSE, D. E. JENNINGS & R. H. HUNT

115 Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastrooesophageal reflux disease and normal control subjects. A. C. PERKINS, C. G. WILSON, M. FRIER, P. E. BLACKSHAW, D. JUAN, R. J. DANSEREAU, S. HATHAWAY, Z. LI, P. LONG & R. C. SPILLER

123 Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. THE BRITISH-ITALIAN GALLSTONE STUDY GROUP: M. L. PETRONI, R. P. JAZRAWI, P. PAZZI, A. LANZINI, M. ZUIN, M. G. PIGOZZI, M. FRACCHIA, G. GALATOLA, V. ALVISI, K. W. HEATON, M. PODDA & T. C. NORTHFIELD

129 Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to inteferon. R. COZZOLONGO, R. CUPPONE, V. GIANNUZZI, L. AMATI, L. CARADONNA, V. TAMBORRINO, E. JIRILLO & O. G. MANGHISI

137 Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. P. BYTZER, N. J. TALLEY, M. P. JONES & M. HOROWITZ

143 Letter to the Editors. F. CANDUCCI, V. OJETTI, P. POLA, G. GASBARRINI & A. GASBARRINI

VOLUME 15 NUMBER 2 FEBRUARY

145 Review article: pain versus discomfort—is differentiation clinically useful? V. STANGHELLINI
151 Walking and chewing reduce postprandial acid reflux. B. AVIDAN, A. SONNENBERG, T. G. SCHNELL & S. J. SONTAG
157 Sildenafil inhibits gastroduodenal motility. M. BORTOLOTTI, C. MARI, C. LOPILATO, L. LA ROVERE & M. MIGLIOLI
163 The effect of oral administration of *Lactobacillus GG* on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. A. ARMUZZI, F. CREMONINI, F. BARTOLOZZI, F. CANDUCCI, M. CANDELLI, V. OJETTI, G. CAMMAROTA, M. ANTI, A. DE LORENZO, P. POLA, G. GASBARRINI & A. GASBARRINI
171 Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? H. DORMANN, S. KREBS, U. MUTH-SELBACH, M. CRIEGEE-RIECK, M. RADESPIEL-TRÖGER, M. LEVY, E. G. HAHN, K. BRUNE & T. SCHNEIDER
181 Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during sandostatin LAR. A. MOSCHETTA, M. F. J. STOLK, J. F. REHFELD, P. PORTINCASA, P. H. TH. J. SLEE, H. P. F. KOPPESCHAAR, K. J. VAN ERPECUM & G. P. VANBERGE-HENEGOUWEN
187 Expression and cellular localization of COX-1 and -2 in *Helicobacter pylori* gastritis. F. K. L. CHAN, K. F. TO, Y. P. NG, T. L. LEE, A. S. L. CHENG, W. K. LEUNG & J. J. Y. SUNG
195 Eradication of *Helicobacter pylori* prevents ulcer development in patients with ulcer-like functional dyspepsia. P.-I. HSU, K.-H. LAI, H.-H. TSENG, G.-H. LO, C.-C. LO, C.-K. LIN, J.-S. CHENG, H.-H. CHAN, M.-K. KU, N.-J. PENG, E.-J. CHIEN, W. CHEN & P.-N. HSU
203 Usefulness of *Helicobacter pylori* stool antigen test to monitor resonse to eradication in children. G. ODERDA, A. RAPA, D. MARINELLO, B. RONCHI & A. ZAVALLONE
207 Quality of life in functional dyspepsia: reponsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. N. J. TALLEY, M. VERLINDEN & M. JONES
217 Changing patterns of sedation use for routine out-patient diagnostic gastroscopy between 1989 and 1998. H. E. MULCAHY, E. HENNESSY, P. CONNOR, B. RHODES, S. E. PATCHETT, M. J. G. FARTHING & P. D. FAIRCLOUGH
221 The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis. J. A. TODD, T. WESTON, T. M. MACDONALD, D. A. JOHNSTON & J. F. DILLON
227 Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. V. K. SHARMA, G. I. LEONTIADIS & C. W. HOWDEN
233 Effect of caloric density of a meal on lower oesophageal sphincter motility and gastro-oesophageal reflux in healthy subjects. C. PEHL, A. PFEIFFER, A. WAIZENHOEFER, B. WENDL & W. SCHEPP
241 Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response. J. L. CALLEJA, A. ALBILLOS, I. ROSSI, R. MORENO, F. DOMPER, J. L. MARTÍNEZ & P. ESCARTÍN
251 Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. M. VECCHI, G. MEUCCI, P. GIONCHETTI, M. BELTRAMI, P. DI MAURIZIO, L. BERETTA, E. GANIO, P. USAI, M. CAMPIERI, G. FORNACIARI & R. DE FRANCHIS
257 Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. H. MIZOGUCHI, S. HASE, A. TANAKA & K. TAKEUCHI

VOLUME 15 NUMBER 3 MARCH

269 Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. R. C. FITZGERALD, R. LASCAR & G. TRIADAFILOPOULOS
277 Review article: tegaserod. M. CAMILLERI
291 Review article: a drug therapy for the prevention of variceal haemorrhage. D. TRIPATHI & P. C. HAYES
311 Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. H. BARR, A. J. DIX, C. KENDALL & N. STONE
323 Review article: the prevention of colorectal cancer. I. DOVE-EDWIN & H. J. W. THOMAS
337 Review article: *Mycobacterium avium* subsp. *paratuberculosis* as one cause of Crohn's disease. W. CHAMBERLIN, D. Y. GRAHAM, K. HULTEN, H. M. T. EL-ZIMAITY, M. R. SCHWARTZ, S. NASER, I. SHAFRAN & F. A. K. EL-ZAATARI
347 Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. N. J. TALLEY, K. LAURITSEN, H. TUNTURI-HIHNALA, T. LIND, B. MOUM, C. BANG, T. SCHULZ, T. M. OMLAND, M. DELLE & O. JUNGHARD
355 Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. T. POYNARD, C. REGIMBEAU & Y. BENHAMOU
363 Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. K. R. HERRLINGER, M. K. NOFTZ, K. FELLERMANN, K. SCHMIDT, J. STEINHOFF & E. F. STANGE
371 Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. E. IERARDI, M. PRINCIPI, R. FRANCAVILLA, A. PISANI, M. RENDINA, M. INGROSSO, F. W. GUGLIELMI, C. PANELLA & A. FRANCAVILLA
379 Non-*Helicobacter pylori* bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. S. SANDULEANU, D. JONKERS, A. DE BRUINE, W. HAMEETEMAN & R. W. STOCKBRÜGGER
389 Evaluation of a novel continuous real time ^{13}C urea breath analyser for *Helicobacter pylori*. H. SHIRIN, G. KENET, O. SHEVAH, Y. WARDI, S. BIRKENFELD, M. SHAHMUROV, R. BRUCK, Y. NIV, S. F. MOSS & Y. AVNI
395 Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect *Helicobacter pylori* in stools. F. COSTA, M. G. MUMOLO, M. BELLINI, M. R. ROMANO, M. MANGHETTI, A. PACI, G. MALTINTI & S. MARCHI
403 One-week ranitidine bismuth citrate-based triple therapy for the eradication of *Helicobacter pylori* in Hong Kong with high prevalence of metronidazole resistance. B. C. Y. WONG, W. M. WONG, W. H. WANG, F. M. Y. FUNG, K. C. LAI, K. M. CHU, S. T. YUEN, S. Y. LEUNG, W. H. C. HU, M. F. YUEN, G. K. K. LAU, C. K. CHAN & S. K. LAM
411 Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of *Helicobacter pylori* in a population with a high metronidazole resistance rate. H. FAKHERI, R. MALEKZADEH, S. MERAT, M. KHATIBIAN, A. FAZEL, B. Z. ALIZADEH & S. MASSARRAT
417 Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for *Helicobacter pylori* infection. A. NAGAHARA, H. MIWA, T. YAMADA, A. KUROSAWA, R. OHKURA & N. SATO
423 Validation of a new immunoblot assay for the diagnosis of *Helicobacter pylori* in an Asian population. W. K. LEUNG, T. P. CHOW, E. K. W. NG, F. K. L. CHAN, S. C. S. CHUNG & J. J. Y. SUNG

VOLUME 15 NUMBER 4 APRIL

429 Review article: iron and inflammatory bowel disease. B. OLDENBURG, J. C. KONINGSBERGER, G. P. VAN BERGE HENEGOUWEN, B. S. VAN ASBECK & J. J. M. MARX

439 Review article: food hypersensitivity and irritable bowel syndrome. S. ZAR, D. KUMAR & M. J. BENSON

451 Review article: a molecular rationale for the how, when and why of colorectal cancer screening. R. F. SOUZA

463 Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. F. CORNILLIE, D. SHEALY, G. D'HAENS, K. GEBOES, G. VAN ASSCHE, J. CEUPPENS, C. WAGNER, T. SCHAIBLE, S. E. PLEVY, S. R. TARGAN & P. RUTGEERTS

475 A 10-year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions. P. BLOMQVIST, N. FELTELIUS, R. LÖFTBERG & A. EKBOM

483 Population-based case control study of the safety of sulfasalazine use during pregnancy. B. NØRGÅRD, A. E. CZEIZEL, M. ROCKENBAUER, J. OLSEN & H. T. SØRENSEN

487 Comparative efficacy of new investigational agents against *Helicobacter pylori*. M. S. OSATO, S. G. REDDY, A. A. PIERGIES, W. J. BOCHENEK, R. T. TESTA & D. Y. GRAHAM

493 High prevalence of mixed infections by *Helicobacter pylori* in Hong Kong: metronidazole sensitivity and overall genotype. B. C. Y. WONG, W. H. WANG, D. E. BERG, F. M. Y. FUNG, K. W. WONG, W. M. WONG, K. C. LAI, C. H. CHO, W. M. HUI & S. K. LAM

505 An evaluation of invasive and non-invasive tests for the diagnosis of *Helicobacter pylori* infection in Chinese. B. C. Y. WONG, W. M. WONG, W. H. WANG, V. S. Y. TANG, J. YOUNG, K. C. LAI, S. T. YUEN, S. Y. LEUNG, W. H. C. HU, C. K. CHAN, W. M. HUI & S. K. LAM

513 Nitrofurantoin quadruple therapy for *Helicobacter pylori* infection: effect of metronidazole resistance. D. Y. GRAHAM, M. A. SAEED, J. HOFFMAN, H. M. T. EL-ZIMAITY, D. H. KWON & M. S. OSATO

519 Maximal acid reflux control for Barrett's oesophagus: feasible and effective. R. SRINIVASAN, P. O. KATZ, A. RAMAKRISHNAN, D. A. KATZKA, M. F. VELA & D. O. CASTELL

525 A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. N. J. TALLEY, S. V. VAN ZANTEN, L. R. SAEZ, G. DUKES, T. PERSCHY, M. HEATH, C. KLEOUDIS & A. W. MANGEL

539 Effect of nabumetone and aspirin on colonic mucosal bleeding time. M. D. BASSON, L. PANZINI & R. H. PALMER

543 Relationship between lactose digestion, gastrointestinal transit time and symptoms in lactose malabsorbers after dairy consumption. I. LABAYEN, L. FORGA, A. GONZÁLEZ, I. LENOIR-WIJNKOOP, R. NUTR & J. A. MARTÍNEZ

551 Induction interferon therapy in na patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. A. S. HADZIYANNIS, C. PAPAIOANNOU, F. SPANOU, E. K. MANESIS & S. J. HADZIYANNIS

559 Letters to the Editors. T. J. HUMPHRIES; H. L. WALDUM & E. BRENNA; M. GUSLANDI; J. GREEN, C. RICHARDSON, R. MARSHALL, J. RHODES, H. MCKIRDY, G. THOMAS & G. WILLIAMS; H. SCHWÖRER, T. LORF, B. RINGE & G. RAMADORI

VOLUME 15 NUMBER 5 MAY

563 Review article: the management of severe Crohn's disease. M. PARKES & D. P. JEWELL

575 Review article: current endoscopic therapeutic options in the management of variceal bleeding. A. HELMY & P. C. HAYES

595 Review article: erythromycin as a prokinetic agent in infants and children. J. I. CURRY, T. D. LANDER & M. D. STRINGER

605 Review article: colon cleansing preparation for gastrointestinal procedures. T. K. TOLEDO & J. A. DIPALMA

613 A systematic comparison of triple therapies for treatment of *Helicobacter pylori* infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. M. J. R. JANSSEN, A. H. A. M. VAN OIJEN, A. L. M. VERBEEK, J. B. M. J. JANSEN & W. A. DE BOER

625 Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. N. D. HAWKES, C. RICHARDSON, B. K. EVANS, J. RHODES, S. J. LEWIS & G. A. O. THOMAS

631 Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. M. R. ARGUEDAS, G. R. HEUDEBERT & C. M. WILCOX

639 Enhanced mucosal fibrinolytic activity in gastroduodenal ulcer haemorrhage and the beneficial effect of acid suppression. E. M. VREEBURG, M. LEVI, E. A. J. RAUWS, S. J. H. V. DEVENTER, P. SNEL, J. W. F. M. BARTELSMAN, J. W. TEN CATE & G. N. J. TYTGAT

647 Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. P. O. KATZ, S. XUE & D. O. CASTELL

653 Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. B. COULIE, M. CAMILLERI, A. E. BHARUCHA, W. J. SANDBORN & D. BURTON

665 *In-vitro* cyclosporin sensitivity of proliferating lymphocytes is predictive of *in-vivo* therapeutic response in ulcerative colitis. G. McCORMACK, D. O'DONOGHUE & A. BAIRD

669 A randomized controlled crossover study comparing synthetic porcine and human secretins with biologically derived porcine secretin to diagnose Zollinger–Ellison Syndrome. D. C. METZ, M. BUCHANAN, E. PURICH & S. FEIN

677 Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. T. POHLE, T. BRZOZOWSKI, J. C. BECKER, I. R. VAN DER VOORT, A. MARKMANN, S. J. KONTUREK, A. MONICZEWSKI, W. DOMSCHKE & J. W. KONTUREK

689 Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. G. V. PAPATHEODORIDIS, V. C. PAPADIMITROPOULOS & S. J. HADZIYANNIS

699 Rapid detection of anti-*Helicobacter pylori* IgG in urine using immunochromatography. D. Y. GRAHAM & S. REDDY

703 Evaluation of five commercial serological tests for the detection of *Helicobacter pylori* infection in Chinese. M. L. SZETO, C. K. LEE, Y. K. YEE, K. F. LI, W. K. LEE, C. C. LEE, T. L. QUE & B. C. Y. WONG

707 Impact of *Helicobacter pylori* resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy. J. TANKOVIC, D. LAMARQUE, C. LASCOLS, C. J. SOUSSY & J. C. DELCHIER

715 Polaprezinc attenuates the *Helicobacter pylori*-induced gastric mucosal leukocyte activation in Mongolian gerbils—a study using intravital videomicroscopy. H. SUZUKI, M. MORI, K. SETO, M. MIYAZAWA, A. KAI, M. SUEMATSU, T. YONETA, S. MIURA & H. ISHII

727 Letters to the Editors. I. L. P. BEALES; S. J. KONTUREK; H. L. WALDUM

VOLUME 15 NUMBER 6 JUNE

731 Review article: the genetics of inflammatory bowel disease. T. AHMAD, J. SATSANGI, D. MCGOVERN, M. BUNCE & D. P. JEWELL

749 Review article: the therapy of constipation. L. R. SCHILLER

765 Review article: acid suppression in the management of gastro-oesophageal reflux disease—an appraisal of treatment options in primary care. R. JONES & P. BYTZER

773 Guidelines for adults on self-medication for the treatment of acute diarrhoea. D. WINGATE, S. F. PHILLIPS, S. J. LEWIS, J.-R. MALAGELADA, P. SPEELMAN, R. STEFFEN & G. N. J. TYTGAT

783 Abnormal bone turnover in long-standing Crohn's disease in remission. E. J. SCHOON, B. G. GEERLING, I. M. A. VAN DOOREN, L. J. SCHURGERS, C. VERMEER, R.-J. M. BRUMMER & R. W. STOCKBRÜGGER

793 Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Y. HORAI, M. KIMURA, H. FURUIE, K. MATSUGUMA, S. IRIE, Y. KOGA, T. NAGAHAMA, M. MURAKAMI, T. MATSUI, T. YAO, A. URAE & T. ISHIZAKI

805 The effect of *Helicobacter pylori* eradication therapy on dyspepsia symptoms in industrial workers in Japan. T. AZUMA, Y. ITO, H. SUTO, M. OHTANI, M. DOJO, A. MURAMATSU, M. KURIYAMA & T. KATO

813 Increased gastric acid secretion after *Helicobacter pylori* eradication may be a factor for developing reflux oesophagitis. T. KOIKE, S. OHARA, H. SEKINE, K. IIJIMA, K. KATO, T. TOYOTA & T. SHIMOSEGAWA

821 Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and *Helicobacter pylori* infection. G. CAPURSO, B. ANNIBALE, J. OSBORN, G. D'AMBRA, G. MARTINO, E. LAHNER & G. DELLE FAVE

831 Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. L. A. FISCHBACH, P. CORREA, H. RAMIREZ, J. L REALPE, T. COLLAZOS, B. RUIZ, L. E. BRAVO, J. C. BRAVO, A. L. CASABON & B. A. SCHMIDT

843 Three-day lansoprazole quadruple therapy for *Helicobacter pylori*-positive duodenal ulcers: a randomized controlled study. B. C. Y. WONG, W. H. WANG, W. M. WONG, G. K. K. LAU, F. M. Y. FUNG, N. N. S. KUNG, K. M. CHU, K. C. LAI, W. H. C. HU, F. L. HU, X. G. LIU, C. K. CHAN, M. F. YUEN, W. M. HUI & S. K. LAM

851 Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for *Helicobacter pylori* eradication. R. MEIER, A. WETTSTEIN, J. DREWE & H. R. GEISER THE SWISS *HELICOBACTER*-STUDY GROUP

857 Bolus somatostatin but not octreotide reduces hepatic sinusoidal pressure by a NO-independent mechanism in chronic liver disease. E. MATRELLA, V. VALATAS, G. NOTAS, H. ROUMPAKI, C. XIDAKIS, A. HADZIDAKIS, I. MOUZAS & E. KOUROUMALIS

865 Pioglitazone, a specific PPAR-γ ligand, inhibits aspirin-induced gastric mucosal injury in rats. Y. NAITO, T. TAKAGI, K. MATSUYAMA, N. YOSHIDA & T. YOSHIKAWA

875 Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by *Helicobacter pylori* infection in C57BL/6 mice. F. XIAO, T. FURUTA, M. TAKASHIMA, N. SHIRAI & H. HANAI

VOLUME 15 NUMBER 7 JULY

887 Review article: the pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders. T. A. COOK, A. F. BRADING & N. J. McC. MORTENSEN

899 Review article: photodynamic therapy and the alimentary tract. C. R. SELVASEKAR, N. BIRBECK, T. MCMILLAN, M. WAINWRIGHT & S. J. WALKER

917 Proton pump inhibitors versus H_2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. J. P. GISBERT, L. GONZÁLEZ, X. CALVET, M. ROQUÉ, R. GABRIEL & J. M. PAJARES

927 The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. N. B. VAKIL, R. SHAKER, D. A. JOHNSON, T. KOVACS, R. D. BAERG, C. HWANG, D. D'AMICO & B. HAMELIN

937 The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young. S. APPEL-DINGEMANSE, A. HOROWITZ, J. CAMPESTRINI, S. OSBORNE & J. MCLEOD

945 Healthcare resource utilization in the management of oesophageal adenocarcinoma. A. SONI & A. SONNENBERG

953 High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. V. DI MARCO, A. VACCARO, D. FERRARO, G. ALAIMO, V. RODOLICO, P. PARISI, S. PERALTA, R. DI STEFANO, P. L. ALMASIO & A. CRAXÌ

959 Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. G. F. LONGSTRETH, C. J. HAWKEY, E. A. MAYER, R. H. JONES, J. NAESDAL, I. K. WILSON, R. A. PEACOCK & I. K. WIKLUND

965 Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. P. A. TESTONI, F. BAGNOLO, A. ANDRIULLI, G. BERNASCONI, S. CROTTA, F. LELLA, A. LOMAZZI, G. MINOLI, C. NATALE, A. PRADA, G. L. TOTI & A. ZAMBELLI

973 Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia. P. KELLY, J. MUSUKU, E. KAFWEMBE, G. LIBBY, I. ZULU, J. MURPHY & M. J. G. FARTHING

981 Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients. M. J. SHAW, T. J. BEEBE, S. A. ADLIS & N. J. TALLEY

989 Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis-related proteins Bax and Bcl-2, and gastrin in human gastric cancer. P. C. KONTUREK, S. J. KONTUREK, Z. SULEKOVA, H. MEIXNER, W. BIELANSKI, T. STARZYNSKA, E. KARCZEWSKA, K. MARLICZ, J. STACHURA & E. G. HAHN

1001 The Loiano-Monghidoro population-based study of *Helicobacter pylori* infection: prevalence by ^{13}C-urea breath test and associated factors. F. BAZZOLI, D. PALLI, R. M. ZAGARI, D. FESTI, P. POZZATO, G. NICOLINI, G. MASALA, S. FOSSI, L. RICCIARDIELLO, D. PANUCCIO & E. RODA

1009 Economic analysis of four triple regimens for the treatment of *Helicobacter pylori*-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. J. H. S. YOU, K. K. C. LEE, S. S. S. HO, J. J. Y. SUNG, N. N. S. KUNG, M. YUNG, C. LEE & G. C. YEE

1017 Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? F. PERRI, M. R. VILLANI, M. QUITADAMO, V. ANNESE, G. A. NIRO & A. ANDRIULLI

1023 Predictors of failure of *Helicobacter pylori* eradication with the standard 'Maastricht triple therapy'. F. PERRI, M. R. VILLANI, V. FESTA, M. QUITADAMO & A. ANDRIULLI

1031 Cure of *Helicobacter pylori* infection in elderly subjects: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. A. PILOTTO, M. FRANCESCHI, G. LEANDRO, L. BOZZOLA, M. RASSU, G. SOFFIATI, F. DI MARIO & G. VALERIO

1037 Is a one-week course of triple anti-*Helicobacter pylori* therapy sufficient to control active duodenal ulcer? B. TEPES, I. KRIZMAN, M. GORENSEK, M. GUBINA & I. OREL

1047 Arrest of chronic acid suppressant drug use after successful *Helicobacter pylori* eradication in patients with peptic ulcer disease: a six-month follow-up study. G. J. B. HURENKAMP, H. G. L. M. GRUNDMEIJER, A. VAN DER ENDE, G. N. J. TYTGAT, W. J. J. ASSENDELFT & R. W. M. VAN DER HULST

1055 *Helicobacter pylori* infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. R. J. F. LAHEIJ, J. B. M. J. JANSEN, A. L. M. VERBEEK & F. W. A. VERHEUGT

1061 Modified seven-day, quadruple therapy as a first line *Helicobacter pylori* treatment. X. CALVET, N. GARCIA, E. GENÉ, R. CAMPO, E. BRULLET & I. SANFELIU

1067 What is the optimal length of proton pump inhibitor-based triple therapies for *H. pylori*? A cost-effectiveness analysis. X. CALVET, E. GENé, T. LÓPEZ & J. P. GISBERT

1077 Comparison of the effects of concanavalin-A and epidermal growth factor on epithelial cell proliferation in the rat intestine. A. J. FITZGERALD, M. JORDINSON, J. M. RHODES, R. SINGH, J. CALAM & R. A. GOODLAD

1085 Letters to the Editors. K. NEAL & R. LOGAN; L. LAINE

VOLUME 15 NUMBER 8 AUGUST

1087 Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. R. F. SOUZA, C. P. MORALES & S. J. SPECHLER

1101 Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. G. P. AITHAL & J. C. MANSFIELD

1109 Review article: transfusion in gasrointestinal haemorrhage—if, when and how much? J. M. DUGGAN

1115 Review article: lymphatic vessel pumping and inflammation—the role of spontaneous constrictions and underlying electrical pacemaker potentials. P.-Y. VON DER WEID

1131 Real tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. J. S. FRASER, A. F. MULLER, D. J. SMITH, D. J. NEWMAN & E. J. LAMB

1139 A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. J. H. CUMMINGS, S. CHRISTIE & T. J. COLE

1147 Anal sphincter biofeedback and pelvic floor exercises for faecal incontinence in adults—a systematic review. C. NORTON & M. A. KAMM

1155 Ambulatory gastric pH monitoring: proper probe placement and normal values. W. K. FACKLER, M. F. VAEZI & J. E. RICHTER

1163 Double gastric infection with *Helicobacter pylori* and non-*Helicobacter pylori* bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. S. SANDULEANU, D. JONKERS, A. DE BRU, W. HAMEETEMAN & R. W. STOCKBRÜGGER

1177 There are some benefits for eradicating *Helicobacter pylori* in patients with non-ulcer dyspepsia. S. BRULEY DES VARANNES, J. F. FLÉJOU, R. COLIN, M. ZA, A. MEUNIER & C. BIDAUT-MAZEL

1187 Efficacy of ecabet sodium for *Helicobacter pylori* eradication triple therapy in comparison with a lansoprazole-based regimen. K. ADACHI, S. ISHIHARA, T. HASHIMOTO, K. HIRAKAWA, N. ISHIMURA, M. NIIGAKI, T. KAJI, A. KAWAMURA, H. SATO, H. FUJISHIRO, S. HATTORI, M. WATANABE & Y. KINOSHITA

1193 A triple therapy regimen after failed *Helicobacter pylori* treatments. A. ZULLO, C. HASSAN, S. M. A. CAMPO, R. LORENZETTI, I. FEBBRARO, M. DE MATTHAEIS, D. PORTO & S. MORINI

1199 Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. K. D. BARDHAN, D. MORTON, M. J. PERRY, D. S. SANDERS, P. MORRIS, A. ROWLAND, M. THOMPSON, T. R. MITCHELL & P. M. ROBERTS

1205 *Helicobacter pylori* testing in the primary care setting: which diagnostic test should be used? C. F. WEIJNEN, N. J. DE WIT, M. E. NUMANS, E. J. KUIPERS, A. W. HOES & T. J. M. VERHEIJ

1211 Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy. T. OSHIMA, K. PAVLICK, M. B. GRISHAM, P. JORDAN, K. MANAS, T. JOH, M. ITOH & J. S. ALEXANDER

1219 Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. L. O'MAHONY, M. FEENEY, S. O'HALLORAN, L. MURPHY, B. KIELY, J. FITZGIBBON, G. LEE, G. O'SULLIVAN, F. SHANAHAN & J. K. COLLINS

1227 Interleukin-8 increases acetylcholine response of rat intestinal segments. V. PLATTNER, V. LERAY, M.-D. LECLAIR, A.-C. AUBÉ, C. CHERBUT & J. P. GALMICHE

1233 Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function. K. NOGI, K. HARUMA, H. TANIGUCHI, E. YOMOTA, M. OKAJIMA, M. HANAOKI, J. HATA, H. KUSUNOKI & Y. ONODA

VOLUME 15 NUMBER 9 SEPTEMBER

1239 Review article: herbal treatment in gastrointestinal and liver disease—benefits and dangers. L. LANGMEAD & D. S. RAMPTON

1253 Review article: current therapeutic options for radiation proctopathy. J. J. HONG, W. PARK & E. D. EHRENPREIS

1263 Review article: over-the-counter drugs and the gastrointestinal tract. C. L. SHEEN & D. G. COLIN-JONES

1271 Review article: pathogenesis of *Helicobacter pylori*-induced gastric inflammation. D. A. ISRAEL & R. M. PEEK

1291 H_2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. H. A. REDSTONE, N. BARROWMAN & S. J. O. VELDHUYZEN VANZANTEN

1301 Chronic use of non-steroidal anti-inflammatory drugs does not alter colonic mucosa of patients without diarrhoea. L. BEAUGERIE, F. BERENBAUM, D. BERREBI, J. P. GENDRE, A. PRIER, G. KAPLAN & F. P. CHATELET

1307 Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. G. C. ACTIS, F. BRESSO, M. ASTEGIANO, B. DEMARCHI, N. SAPONE, C. BOSCAGLIA & M. RIZZETTO

1313 Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. W. REINISCH, H. NAHAVANDI, R. SANTELLA, Y. ZHANG, C. GASCHÉ, G. MOSER, T. WALDHÖR, A. GANGL, H. VOGELSANG & R. KNOBLER

1323 Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multicentre clinical trial in active Crohn's disease. E. CARTY, D. S. RAMPTON, H. SCHNEIDER, P. RUTGEERTS & J. P. WRIGHT

1331 Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. J. R. B. GREEN, A. J. LOBO, M. GIAFFER, S. TRAVIS, H. C. WATKINS & THE FREEDOM INVESTIGATOR GROUP

1343 Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. J. P. GALMICHE, F. ZERBIB, P. DUCROTTÉ, J. FOURNET, P. RAMPAL, N. AVASTHY & T. J. HUMPHRIES

1351 Bedtime H_2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. S. XUE, P. O. KATZ, P. BANERJEE, R. TUTUIAN & D. O. CASTELL

1357 The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. N. J. TRUDGILL, F. N. HUSSAIN, M. MOUSTAFA, R. AJJAN, M. D'AMATO & S. A. RILEY

1365 Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn. M. ROBINSON, S. RODRIGUEZ-STANLEY, A. A. CIOCIOLA, J. FILINTO, S. ZUBAIDI, P. B. MINER JR & J. D. GARDNER

1375 Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. P. NETZER, A. GUT, R. BRUNDLER, C. GAIA, F. HALTER & W. INAUEN

1385 The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease. W. C. ORR , C.-L. CHEN & S. SLOAN

1389 Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. J. MIKAELI, A. FAZEL, G. MONTAZERI, M. YAGHOOBI & R. MALEKZADEH

1397 Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. C. FAURE, L. MICHAUD, E. KHAN SHAGHAGHI, M. POPON, M. LAURENCE, J. F. MOUGENOT, R. HANKARD, J. NAVARRO & E. JACQZ-AIGRAIN

1403 When William of Ockham meets Thomas Bayes: finding a few diagnoses among a great many symptoms. A. SONNENBERG

1409 Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. J. J. ORTIZ, A. AYOUB, G. GARGALA, N. L. CHEGNE & L. FAVENNEC

1417 *In vivo* and *in vitro* permeability in coeliac disease. H. VOGELSANG, M. SCHWARZENHOFER, B. STEINER, J. WYATT & G. OBERHUBER

1427 Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. P. M. BATTEZZATI, M. ZUIN, A. CROSIGNANI, M. ALLOCCA, P. INVERNIZZI, C. SELMI, E. VILLA & M. PODDA

1435 Octreotide increases the proportions of arachidonic acid-rich phospholipids in gall-bladder bile. S. P. PEREIRA, S. H. HUSSAINI, G. M. MURPHY, J. A. H. WASS & R. H. DOWLING

1445 Influence of anti-*Helicobacter* triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. A. BÜHLING, D. RADUN, W. A. MÜLLER & P. MALFERTHEINER

Continued

Continued

1453 Outcomes of *H. pylori* treatment in community practice and impact of therapeutic effectiveness information on physician behaviour. M. B. FENNERTY, N. MARGARET, L. DALROS, D. FAIGEL, D. LIEBERMAN & M. SHAW

1459 Epidermal growth factor and its receptor in chronic active gastritis and gastroduodenal ulcer before and after *Helicobacter pylori* eradication. B. CHUN YU WONG, W. PING WANG, W. HAU LEUNG SO, V. Y. SHIN, W. MAN WONG, F. MAN YEE FUNG, E. SHIU LAM LIU, W. MO HIU, S. KUM LAM & C. HIN CHO

1467 Apoptosis and proliferation in *Helicobacter pylori*-associated gastric intestinal metaplasia. W. K. LEUNG, J. YU, K. F. TO, M. Y. Y. GO, P. K. MA, F. K. L. CHAN & J. J. Y. SUNG

1473 *Helicobacter pylori* antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. H. K. PARSONS, M. J. CARTER, D. S. SAUNDERS, T. WINSTANLEY & A. J. LOBO

1479 Efficacy of triple therapy with rabeprazole for *Helicobacter pylori* infection and CYP2C19 genetic polymorphism. K. HOKARI, T. SUGIYAMA, M. KATO, M. SAITO, T. MIYAGISHIMA, M. KUDO, K. NISHIKAWA, J. ISHIZUKA, Y. KOMATSU, T. MIZUSHIMA, H. KAGAYA, S. HIGE, H. TAKEDA & M. ASAKA

1485 Intragastric distribution of *Helicobacter pylori* during short-term omeprazole therapy: study using Carnoy's fixation and immunohistochemistry for detection of bacteria. S. ISHIHARA, T. OKUYAMA, N. ISHIMURA, M. ONO, T. HASHIMOTO, H. KAZUMORI, T. KAJI, H. SATO, H. FUJISHIRO, K. ADACHI, R. FUKUDA & Y. KINOSHITA

1493 Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for *Helicobacter pylori* eradication. D. KAMBEROGLOU, D. POLYMEROS, I. SANIDAS, V. DOULGEROGLOU, S. SAVVA, E. PATRA & V. TZIAS

1499 Twenty-minute 50 mg ^{13}C-urea breath test without test meal for the diagnosis of *Helicobacter pylori* infection in Chinese. W. M. WONG, B. C. Y. WONG, T. M. LI, K. W. WONG, K. L. CHEUNG, F. M. Y. FUNG, H. H. X. XIA & S. K. LAM

1505 Effect of *Helicobacter pylori* eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. J. YU, W. K. LEUNG, E. K. W. NG, K. F. TO, M. P. A. EBERT, M. Y. Y. GO, W. Y. CHAN, F. K. L. CHAN, S. C. S. CHUNG, P. MALFERTHEINER & J. J. Y. SUNG

1513 Corrigenda

VOLUME 15 NUMBER 10 OCTOBER

1515 Review article: the limitations of corticosteroid therapy in Crohn's disease. P. J. RUTGEERTS
1527 Review article: non-systemic chemotherapy in the treatment of colorectal cancer—portal vein, hepatic arterial and intraperitoneal approaches. B. BUECHER & H. BLEIBERG
1543 Review article: alternative antibacterial agents for *Helicobacter pylori* eradication. M. GUSLANDI
1549 Review article: balsalazide therapy in ulcerative colitis. K. RAGUNATH & J. G. WILLIAMS
1555 Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger–Ellison syndrome? V. D. CORLETO, B. ANNIBALE, F. GIBRIL, S. ANGELETTI, J. SERRANO, D. J. VENZON, G. DELLA FAVE & R. T. JENSEN
1563 Pharmacokinetics and pharamcodynamics of esomeprazole, the S-isomer of omeprazole. T. ANDERSSON, K. RÖHSS, E. BREDBERG & M. HASSAN-ALIN
1571 Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. K. PAUL, C. M. REDMAN & M. CHEN
1579 Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine. M. I. HAMILTON, J. SERCOMBE & R. E. POUNDER
1585 Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omepraxole in patients with grade I reflux oesophagitis. K. D. BARDHAN & C. VAN RENSBURG (ON BEHALF OF THE INVESTIGATORS)
1593 Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. C. J. HAWKEY, L. LAINE, S. E. HARPER, H. U. I. QUAN, J. A. BOLOGNESE & E. MORTENSEN FOR THE ROFECOXIB OSTEOARTHRITIS ENDOSCOPY MULTINATIONAL STUDY GROUP
1603 Double-blind placebo-controlled multicenter studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without *Helicobacter pylori* infection. N. J. TALLEY, D. S. RIFF, H. SCHWARTZ & S. P. MARCUARD
1613 A double-blind placebo controlled study of buspirone-stimulated prolactin release in nonulcer dyspepsia—are central serotoninergic responses enhanced? T. G. DINAN, N. MAHMUD, O. RATHORE, J. THAKORE, L. V. SCOTT, E. CARR, J. NAESDAL, C. A. O'MORAIN & P. W. N. KEELING
1619 Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. A. CARROCCIO, A. GUARINO, G. ZUIN, F. VERGHI, R. BERNI CANANI, M. FONTANA, E. BRUZZESE, G. MONTALTO & A. NOTARBARTOLO
1627 Antiretroviral hepatoxicity in human immunodeficiency virus-infected patients. L. V. HERNANDEZ, I. GILSON, J. JACOBSON, A. AFFI, T. R. PUETZ & V. J. DINDZANS
1633 Acute cholangitis—predictive factors for emergency ERCP. C.-K. HUI, K.-C. LAI, M.-F. YUEN, M. NG, C.-L. LAI & S.-K. LAM
1639 Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. I. D. R. ARNOTT, D. MCDONALD, A. WILLIAMS & S. GHOSH
1647 Immune sensitization to food, yeast and bacteria in Crohn's disease. J. VAN DEN BOGAERDE, M. A. KAMM & S. C. KNIGHT
1655 Tegaserod, a 5-HT_4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. S. A. MÜLLER-LISSNER, I. FUMAGALLI, K. D. BARDHAN, F. PACE, E. PECHER, B. NAULT & P. RÜEGG
1667 Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. T. HASEGAWA, M. YONEDA, K. NAKAMURA, I. MAKINO & A. TERANO
1673 Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth factor. P. NETZER, M. DOMEK, R. PAI, F. HALTER & A. TARNAWSKI
1681 Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat. M. SASAKI, A. J. FITZGERALD, N. MANDIR, K. SASAKI, N. A. WRIGHT & R. A. GOODLAD
1687 Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. I. DOTAN, R. HERSHKOVIZ, F. KARMELI, E. BRAZOWSKI, Y. PELED, D. RACHMILEWITZ & Z. HALPERN

VOLUME 15 NUMBER 11 NOVEMBER

1699 Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. O. H. NIELSEN, D. VAINER & J. RASK-MADSEN

1709 Review article: the immunoregulatory cytokine interleukin-10—a therapy for Crohn's disease? J. O. LINDSAY & H. J. F. HODGSON

1717 Review article: the pharmacological treatment of acute colonic pseudo-obstruction. R. DE GIORGIO, G. BARBARA, V. STANGHELLINI, M. TONINI, V. VASINA, B. COLA, R. CORINALDESI, G. BIAGI & F. DE PONTI

1729 Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. S. J. EDWARDS, T. LIND & L. LUNDELL

1737 Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. S. W. C. TSANG, H. L. Y. CHAN, N. W. Y. LEUNG, T. N. CHAU, S. T. LAI, F. K. L. CHAN & J. J. Y. SUNG

1745 Tegaserod, a 5-HT_4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. L. DEGEN, D. MATZINGER, M. MERZ, S. APPEL-DINGEMANSE, S. OSBORNE, S. LÜCHINGER, R. BERTOLD, H. MAECKE & C. BEGLINGER

1753 Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with *Helicobacter pylori* infection. G. CAPURSO, E. LAHNER, A. MARCHEGGIANO, P. CARUANA, A. CARNUCCIO, C. BORDI, G. DELLE FAVE & B. ANNIBALE

1763 Citric acid enhanced *Helicobacter pylori* urease activity *in vivo* is unrelated to gastric emptying. A. SHIOTANI, A. SAEED, Y. YAMAOKA, M. S. OSATO, P. D. KLEIN & D. Y. GRAHAM

1769 Lack of symptom benefit following presumptive *Helicobacter pylori* eradication therapy in primary care. D. WILLIAMS, P. O'KELLY, A. KELLY & J. FEELY

1777 Evaluation of the cost-effectiveness of *Helicobacter pylori* eradication triple therapy vs. conventional therapy for ulcers in Japan. S. IKEDA, T. TAMAMURO, C. HAMASHIMA & M. ASAKA

1787 A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. J. LAURENT, F. MÉGRAUD, J. F. FLÉJOU, A. CAEKAERT & P. BARTHÉLEMY

1795 Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. B. I. HIRSCHOWITZ, J. SIMMONS & J. MOHNEN

1807 A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. J. J. TÄUBEL, V. K. SHARMA, Y. L. CHIU, N. L. LUKASIK, B. L. PILMER & W. J. PAN

1819 Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. K. GEBOES, W. DEKKER, C. J. J. MULDER & K. NUSTELING (ON BEHALF OF THE DUTCH STUDY GROUP)

1827 Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indomethacin-induced bowel inflammation model. S. COLPAERT, Z. LIU, B. DE GREEF, P. RUTGEERTS, J. L. CEUPPENS & K. GEBOES

1837 A study of the effects of indomethacin on liver mitochondria from rats, mice and humans. M. JACOB, I. BJARNASON, S. RAFI, J. WIGGLESWORTH & R. J. SIMPSON

VOLUME 15 NUMBER 12 DECEMBER

1843 Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? J. R. BEBB & R. P. H. LOGAN

1851 Review article: spontaneous bacterial peritonitis—diagnosis, treatment and prevention. C. MOWAT & A. J. STANLEY

1861 Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. R. W. GOODGAME, K. KIMBALL, S. AKRAM, E. IKE, C.-N. OU, F. SUTTON & D. GRAHAM

1867 Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial. N. D. HAWKES, C. RICHARDSON, C. L. CH'NG, J. T. GREEN, B. K. EVANS, J. WILLIAMS, P. RHODES, J. RHODES, G. L. SWIFT, G. A. O. THOMAS, A. B. HAWTHORNE, J. G. C. KINGHAM & J. F. MAYBERRY

1875 Clinical and endoscopic characteristics of non-*Helicobacter pylori*, non-NSAID duodenal ulcers: a long-term prospective study. H. H.-X. XIA, B. C. Y. WONG, K. W. WONG, S. Y. WONG, W. M. WONG, K. C. LAI, W. H. C. HU, C. K. CHAN & S. K. LAM

1883 Methicillin-resistant *Staphylococcus aureus* infection of percutaneous endoscopic gastrostomy sites. M. HULL, A. BEANE, J. BOWEN & C. SETTLE

1889 Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. A. SZILAGYI & I. SHRIER

1899 The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. H. L.-Y. CHAN, J.-L. TANG, W. TAM & J. J.-Y. SUNG

1907 Reflux symptoms are associated with psychiatric disease. B. AVIDAN, A. SONNENBERG, H. GIBLOVICH & S. J. SONTAG

1913 Dysfunction of oesophageal motility in *Helicobacter pylori*-infected patients with reflux oseophagitis. J. C. Y. WU, A. C. W. LAI, S. K. H. WONG, F. K. L. CHAN, W.-K. LEUNG & J. J. Y. SUNG

1921 Effect of inhibition of gastric acid secretion on antropyloroduodenal motor activity and duodenal acid hypersensitivity in functional dyspepsia. M. P. SCHWARTZ, M. SAMSOM, G. P. VAN BERGE HENEGOUWEN & A. J. P. M. SMOUT

1929 Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. N. SHIRAI, T. FURUTA, Y. MORIYAMA, H. OKOCHI, K. KOBAYASHI, M. TAKASHIMA, F. XIAO, K. KOSUGE, K. NAKAGAWA, H. HANAI, K. CHIBA, K. OHASHI & T. ISHIZAKI

1939 *Helicobacter pylori* eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. V. K. SHARMA, A. V. SAHAI, F. A. CORDER & C. W. HOWDEN

1949 A meta-analysis comparing eradication, healing and relapse rates in patients with *Helicobacter pylori*-associated gastric or duodenal ulcer. A. LEODOLTER, M. KULIG, H. BRASCH, W. MEYER-SABELLEK, S. N. WILLICH & P. MALFERTHEINER

1959 Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of *Helicobacter pylori* infection. B. C. Y. WONG, W. M. WONG, Y. K. YEE, W. K. HUNG, A. W. C. YIP, M. L. SZETO, K. F. LI, P. LAU, F. M. Y. FUNG, T. S. M. TONG, K. C. LAI, W. H. C. HU, M. F. YUEN, C. K. HUI & S. K. LAM

1967 Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with *Helicobacter pylori* infection. E. GIANNINI, A. FASOLI, P. BORRO, B. CHIARBONELLO, F. MALFATTI, P. ROMAGNOLI, F. BOTTA, E. TESTA, A. FUMAGALLI, S. POLEGATO, V. SAVARINO & R. TESTA

1975 One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate *Helicobacter pylori*: a multicentre, randomized, double-blind study. H. LU, D.-Z. ZHANG, P.-J. HU, Z.-S. LI, X.-H. LU, X.-C. FANG & S.-D. XIAO

1981 Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model. A. M. SMITH, T. MORRIS, T. JUSTIN, D. MICHAELI & S. A. WATSON

1989 Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. J. CARRIER, E. AGHDASSI, I. PLATT, J. CULLEN & J. P. ALLARD

2001 Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. J. TIBBLE, G. SIGTHORSSON, C. CALDWELL, R. H. PALMER & I. BJARNASON

2009 A 3.0-kDa low molecular weight heparin promotes gastric ulcer healing in rats. Y. LI, V. Y. SHIN, C. Y. CHEUK, E. S. L. LIU & C. H. CHO

2019 Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. A. MILLER-LARSSON, B. GUSTAFSSON, C. G. A. PERSSON & R. BRATTSAND

2027 Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat. J. GáLVEZ, G. COELHO, M. E. CRESPO, T. CRUZ, M. E. RODRíGUEZ-CABEZAS, A. CONCHA, M. GONZALEZ & A. ZARZUELO

2041 Letter to the Editors. H. W. VERSPAGET, A. M. VAN DER ZON, Q. GAO & R. A. VAN HOGEZAND

2043 Index